Increasing numbers of patients with breast cancer receive neoadjuvant therapies. We investigated differences in survival rates between geriatric and non-geriatric patient groups following administration of neoadjuvant therapies. Materials and Method: We examined 166 patients who received neoadjuvant therapy for breast cancer between 2007 and 2016. Patients <70 years were in Group 1 and those ≥70 years were in Group 2. We retrospectively compared age, sex, treatment, tumour stage and

more »

... , status of oestrogen and progesterone receptors, involvement of axillary lymph nodes, systemic treatment complications, treatment compliance and survival rates using a variety of parametric and non-parametric statistical tests. Results: The mean ages of patients in Group 1 (n = 136) and Group 2 (n = 30) were 44.6 ± 8.92 and 76.7 ± 5.48 years, respectively. The most common tumour location was the upper-outer quadrant. All patients received treatment consisting of 4AC (doxorubicincyclophosphamide) + 4 taxane or 4AC (doxorubicin-cyclophosphamide) + paclitaxel for 12 weeks. Neither group exhibited mortality or complications requiring treatment interruption. Breast-conserving surgery was performed in 88 (53%) patients. Complete response was achieved in 14 (8%) patients after surgery. Mean tumour diameters in Groups 1 and 2 were 26.8 mm (±27.59) and 28.5 mm (±40.23), respectively. Five-year general survival rates were %69,7 in Group 1 and % 70 in Group 2( p = 0.94). Conclusion: Neoadjuvant therapy is a reliable treatment option in patients ≥70 years who are candidates for chemotherapy, since complication and mortality rates did not increase compared with younger patients.